I. Why Xinjiang Pharmaceuticals Warrant Separate Study

Within China's national pharmaceutical manufacturing landscape, Xinjiang's footprint is modest. In 2024, the region's total pharmaceutical industrial output value was approximately 13.8 billion yuan — a figure that leading pharma companies in Zhejiang or Jiangsu could individually surpass.

Yet beyond scale, Xinjiang pharmaceuticals possess two assets that are difficult to replicate elsewhere, making them worthy of dedicated analysis.

The first is Uyghur medicine (known in Chinese as "Wei Yao"). Uyghur medicine evolved from centuries of traditional Uyghur medical knowledge. It holds nationally exclusive approval numbers for certain formulations, with some products listed in the National Essential Medicines Catalogue and under traditional medicine protection status — a niche that outside competitors cannot easily enter.

The second is authentic regional medicinal herb resources. Xinjiang is one of the country's most important production regions for licorice, safflower, Apocynum venetum (luobuma), Cistanche (roucongrong), and Fritillaria thunbergii. Yumin County in Tacheng Prefecture cultivates safflower on 110,000 mu, accounting for approximately 70% of national output. This resource advantage, if processed locally into higher-value products, constitutes a substantial industry barrier.

It is these two assets — not volume — that give Xinjiang pharmaceutical manufacturing a structural logic worth examining.

II. Uyghur Medicine: The Line With the Deepest Heritage and Highest Barriers

Uyghur medicine occupies a special position in Xinjiang's pharmaceutical landscape, precisely because of the exclusivity of its intellectual property. Unlike generic chemical drugs that face head-to-head price competition, Wei Yao formulations require accumulated traditional knowledge, approved dosage-form registrations, and clinical data — each of which takes years to build, making rapid entry by outside competitors difficult.

Three companies hold meaningful positions in the Wei Yao segment.

Xinjiang Uyghur Pharmaceutical Co., Ltd. has the most complete product portfolio, with 20 national pharmaceutical registration numbers including 12 nationally exclusive products, 4 traditional medicine protected products, 12 products on the national medical insurance list, and 2 in the National Essential Medicines Catalogue. Exclusive listings confer pricing power: Wei Yao products on the insurance list are largely shielded from generic competition, giving them more stable margins. In August 2024, the company broke ground on a 5-billion-yuan international industrial park in the Urumqi Free Trade Zone High-Tech functional block, covering nearly 400 mu and designed to produce 400 million boxes of granules, 24 million boxes of liquid preparations, and 53 million boxes of tablets and capsules annually. The park's construction is planned over six to eight years and represents the largest single capital investment by any Wei Yao enterprise to date.

Xinjiang Yindolan Uyghur Pharmaceutical Co., Ltd. stands out for its density of Wei Yao approvals: 97 pharmaceutical production registration numbers in total, of which 12 are specifically Wei Yao registrations. Its flagship product, Zukamu Granules (an anti-cold herbal granule formulation), is listed as a national Class II traditional medicine protected product and enjoys wide retail penetration across northern Xinjiang.

Xinqikang Pharmaceutical has taken a path more oriented toward modern research and development. In 2025, Xinqikang ranked 13th on the "Top 20 Chinese Traditional Medicine R&D Capability" list, having built a full value chain from medicinal herb cultivation to R&D, manufacturing, and sales. Compared with Yindolan's focus on traditional dosage forms, Xinqikang has invested more systematically in standardized decoction pieces and botanical extract product lines.

The common challenge for these three leaders is product pipeline concentration: six individual Wei Yao products each exceed 100 million yuan in annual sales, but a credible "second growth curve" of pipeline products is not yet well-stocked. As national medical insurance negotiations become routine, even exclusive products face incremental pricing pressure. Expanding indications and advancing new drug candidates are the most important medium-term tasks for this segment.

III. Authentic Herbs and Deep Processing: Strong at the Raw Material End, Weak at Processing

If Wei Yao is Xinjiang's pharmaceutical signature, authentic regional herbs are the raw material foundation underpinning that signature — and also the segment where the supply chain is most established yet processing capacity most underdeveloped.

To place the scale of Xinjiang's medicinal herb cultivation: 86 species are cultivated across the region, of which 10 are classified as authentic regional varieties. The top five by area are Cistanche, safflower, licorice, wolfberry, and Apocynum venetum. Pharmaceutical companies using licorice as a primary input have collectively cultivated over 200,000 mu of licorice plantations in the region. The 11,000 mu of safflower in Yumin County alone accounts for roughly 70% of national output. Overall, medicinal herb raw materials generate over 5 billion yuan in annual output value; with full downstream processing, the theoretical value could reach tens of billions.

Yet "full processing" is precisely the gap. Safflower's active components — safflower yellow and hydroxysafflower yellow A — command significant extraction premiums, but local enterprises capable of this depth of processing are few. Most safflower leaves Xinjiang as raw herb material, with value-added extraction performed by manufacturers in inland provinces. The picture for licorice is similar: licorice preparations, extracts, and glycyrrhizic acid derivatives are largely priced and processed outside the region, leaving Xinjiang holding the raw material without fully capturing the value chain.

This "raw material on the frontier, processing in the interior" pattern is common in Chinese agricultural processing, but in a category like medicinal herbs — where product traceability and place of origin are increasingly important — the pattern has room to shift. In recent years, the Xinjiang Agriculture and Rural Affairs Department has promoted standardized cultivation under "company + farmer + base" models, and several Wei Yao leaders have established their own medicinal herb plantations in northern and southern Xinjiang, building raw material security for local processing.

IV. Biopharmaceuticals and Botanical Extracts: Small Scale, Real Potential

Beyond Wei Yao and medicinal herbs, biopharmaceuticals and botanical extracts form a smaller but faster-growing third track in Xinjiang's pharmaceutical landscape.

Xinjiang Tefeng Pharmaceutical is a representative enterprise. The company integrates R&D, manufacturing, and sales, collaborating with Xinjiang Medical University and over ten other academic institutions. Its product range includes lycopene derived from botanical extraction — a product line with direct supply chain logic, since Xinjiang's large-scale processing tomato agriculture provides a natural upstream source for lycopene raw material.

Ili Prefecture is advancing its raw materials pharmaceutical sector, with companies including Kansen Pharmaceutical (Khorgos), Xinjiang Xinziyuan Biopharmaceutical, and Ili Quanlu Pharmaceutical forming a cluster drawing on the Ili River valley's agricultural resources. Ili's industrial zone lists modern traditional medicine, biopharmaceuticals, and chemical pharmaceuticals as priority sectors, though current production scale and technological level remain below those of coastal provinces.

In 2024, Xinjiang's biopharmaceutical industry chain reported revenue of 10.572 billion yuan for the January-to-September period, up 20.1% year-on-year. The same year, drug research and development candidates in Xinjiang reached 124 items, with the region's first Class 1.1 innovative traditional medicine drug — Shenge Bushen Capsules — achieving commercial production. These figures indicate a real industrial base with respectable growth, even if the depth of the research pipeline falls well short of eastern provinces.

V. Industry Geography: The Agglomeration Effect of Urumqi High-Tech Zone

Xinjiang's pharmaceutical manufacturing geography shows pronounced spatial concentration. Urumqi High-Tech Zone (Xinshi District) clusters over 70% of the region's pharmaceutical enterprises, forming a comprehensive industrial cluster covering traditional Chinese medicine, ethnic medicine, biologics, chemical pharmaceuticals, active pharmaceutical ingredients, herbal decoction pieces, nutraceuticals, medical devices, and pharmaceutical packaging.

The zone's strength lies in supporting infrastructure: R&D institutions, testing centers, cold-chain logistics, and regulatory resources are all concentrated here, giving companies more complete support for policy filings, qualification certification, and talent recruitment. The Wei Yao international industrial park's location in the Urumqi Free Trade Zone follows this same logic.

Southern Xinjiang's role remains primarily in raw material supply. Kashgar, Hotan, and Aksu are important bases for Wei Yao ingredient cultivation and primary processing, but high-value-added pharmaceutical production capacity is concentrated in northern Xinjiang. This "raw materials in the south, manufacturing in the north" structure reflects logistics costs, cold-chain infrastructure, and talent distribution — and also points to where further downstream processing capacity could be developed.

VI. Perspective for Upstream Suppliers

The pharmaceutical supply chain in Xinjiang creates upstream procurement demand across several categories: standardized medicinal herb raw materials (direct supply from certified cultivation bases), pharmaceutical excipients and packaging (high-barrier blister packs, aluminum foil), pharmaceutical equipment (granule filling lines, liquid preparation lines, extraction equipment), and cold-chain logistics for biologics and raw materials across regions.

Sales teams supplying Xinjiang's Wei Yao manufacturers and medicinal herb processors can use Tianxia Gongchang to filter factory directories and decision-maker contacts by region and product category, reaching pharmaceutical manufacturing procurement teams directly.

Xinjiang pharmaceutical manufacturing's underlying strength rests on two genuine and scarce assets: centuries of Wei Yao knowledge accumulation and the country's most productive western herb-growing territory. Both assets are currently undermonetized — shallow processing ratios, thin product pipelines — and that gap is precisely the central question for the next phase of development. At 13.8 billion yuan, the region's output value looks less like a ceiling and more like a baseline.

Sources

  • Tianxia Gongchang (Xinjiang pharmaceutical manufacturer directory and industry data)
  • Xinjiang Uyghur Autonomous Region Department of Industry and Information Technology: Reply to Recommendation No. 175 of the Second Session of the 14th People's Congress (July 2024)
  • China News Service: Xinjiang's 2024 pharmaceutical industrial output value approximately 13.8 billion yuan, up 40% year-on-year (February 2025)
  • Tianshan Net: Walking into Private Enterprises — Xinjiang Uyghur Pharmaceutical Deepens Ethnic Medicine Market (November 2023)
  • China Daily Xinjiang: Xinjiang Uyghur Pharmaceutical 5-billion-yuan international industrial park breaks ground (August 2024)
  • Xinjiang Agriculture and Rural Affairs Department: Standardized cultivation and market-oriented management strengthen Xinjiang's medicinal herb industry base (August 2024)
  • Xinjiang Development and Reform Commission: Seizing opportunities to accelerate Xinjiang's biopharmaceutical industry development (February 2023)
  • Tianshan Net: Xinjiang ethnic medicine sales grow significantly, supporting healthcare service center development (November 2023)
  • China News Service: Xinjiang new drug R&D shows positive trends; 124 drug development candidates in 2024 (February 2025)